Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese

NeuroToxicology

Volumn 44, Issue , 2014, Pages 314-325

  Roth, Jerome A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Gene markers; Manganese; Manganism; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ATPASE TYPE 13A2; CELL PROTEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MANGANESE; PARKIN; PARKIN 9 PROTEIN; PROTEIN SLC30A10; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG; VACUOLAR PROTEIN SORTING ASSOCIATED PROTEIN 35; ATP13A2 PROTEIN, HUMAN; CATION TRANSPORT PROTEIN; LRRK2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; PTEN-INDUCED PUTATIVE KINASE; SIGNAL PEPTIDE; SLC30A8 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; VESICULAR TRANSPORT PROTEIN; VPS35 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; CELL DEATH; CELL VACUOLE; DOPAMINERGIC NERVE CELL; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; HUMAN; INTOXICATION; LONG TERM EXPOSURE; MANGANISM; NERVE CELL PLASTICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; ENVIRONMENTAL EXPOSURE; GENETICS; MOUSE; MUTATION; PARKINSONISM; RISK FACTOR; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; CATION TRANSPORT PROTEINS; ENVIRONMENTAL EXPOSURE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MANGANESE; MICE; MUTATION; ONCOGENE PROTEINS; PARKINSONIAN DISORDERS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTON-TRANSLOCATING ATPASES; RISK FACTORS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; VESICULAR TRANSPORT PROTEINS;

EID: 84907344203     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2014.08.006     Document Type: Review

References (197)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Abou-Sleiman P.M., Healy D.G., Quinn N., Lees A.J., Wood N.W. The role of pathogenic DJ-1 mutations in Parkinson's disease. Annals of Neurology 2003, 54:283-286.
3. Aboud A.A., Tidball A.M., Kumar K.K., Neely M.D., Ess K.C., Erikson K.M., et al. Genetic risk for Parkinson's disease correlates with alterations in neuronal manganese sensitivity between two human subjects. Neurotoxicology 2012, 33:1443-1449.
4. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain: A Journal of Neurology 2005, 128:2777-2785.
5. Ashley A.K., Hanneman W.H., Katoh T., Moreno J.A., Pollack A., Tjalkens R.B., et al. Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. Toxicology Letters 2009, 184:186-191.
6. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American Journal of Pathology 1998, 152:879-884.
7. Banerjee K., Sinha M., Pham Cle L., Jana S., Chanda D., Cappai R., et al. Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Letters 2010, 584:1571-1576.
8. Bardien S., Lesage S., Brice A., Carr J. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. Parkinsonism & Related Disorders 2011, 17:501-508.
9. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. The Journal of Biological Chemistry 1999, 274:33855-33858.
10. Bertoncini C.W., Jung Y.S., Fernandez C.O., Hoyer W., Griesinger C., Jovin T.M., et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1430-1435.
11. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology 2006, 60:557-569.
12. Bonifacino J.S., Hurley J.H. Retromer. Current Opinion in Cell Biology 2008, 20:427-436.
13. Bonifacino J.S., Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nature Reviews. Molecular Cell Biology 2006, 7:568-579.
14. Bonifati V., Rizzu P., Squitieri F., Krieger E., Vanacore N., van Swieten J.C., et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2003, 24:159-160.
15. Bonini N.M., Giasson B.I. Snaring the function of alpha-synuclein. Cell 2005, 123:359-361.
16. Brasse-Lagnel C., Karim Z., Letteron P., Bekri S., Bado A., Beaumont C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology 2011, 140(1261-1271):e1261.
17. Bravo-San Pedro J.M., Niso-Santano M., Gomez-Sanchez R., Pizarro-Estrella E., Aiastui-Pujana A., Gorostidi A., et al. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cellular and Molecular Life Sciences: CMLS 2013, 70:121-136.
18. Buchanan R.J., Darrow D.P., Meier K.T., Robinson J., Schiehser D.M., Glahn D.C., et al. Changes in GABA and glutamate concentrations during memory tasks in patients with Parkinson's disease undergoing DBS surgery. Frontiers in Human Neuroscience 2014, 8:81.
19. Cai T., Yao T., Zheng G., Chen Y., Du K., Cao Y., et al. Manganese induces the overexpression of alpha-synuclein in PC12 cells via ERK activation. Brain Research 2010, 1359:201-207.
20. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9103-9108.
21. Chan N.C., Chan D.C. Parkin uses the UPS to ship off dysfunctional mitochondria. Autophagy 2011, 7:771-772.
22. Chartier-Harlin M.C., Dachsel J.C., Vilarino-Guell C., Lincoln S.J., Lepretre F., Hulihan M.M., et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. American Journal of Human Genetics 2011, 89:398-406.
23. Chesi A., Kilaru A., Fang X., Cooper A.A., Gitler A.D. The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. PLoS ONE 2012, 7:e34178.
24. Chien H.F., Bonifati V., Barbosa E.R. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Movement Disorders: Official Journal of the Movement Disorder Society 2011, 26:1364-1365.
25. Chu Y., Dodiya H., Aebischer P., Olanow C.W., Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiology of Disease 2009, 35:385-398.
26. Cirnaru M.D., Marte A., Belluzzi E., Russo I., Gabrielli M., Longo F., et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience 2014, 7:49.
27. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
28. Cordova F.M., Aguiar A.S., Peres T.V., Lopes M.W., Goncalves F.M., Remor A.P., et al. In vivo manganese exposure modulates Erk, Akt and Darpp-32 in the striatum of developing rats, and impairs their motor function. PLoS ONE 2012, 7:e33057.
29. Covy J.P., Giasson B.I. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochemical and Biophysical Research Communications 2009, 378:473-477.
30. Covy J.P., Giasson B.I. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. Journal of Neurochemistry 2010, 115:36-46.
31. Covy J.P., Giasson B.I. alpha-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology 2011, 32:622-629.
32. Criswell S.R., Perlmutter J.S., Crippin J.S., Videen T.O., Moerlein S.M., Flores H.P., et al. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Archives of Neurology 2012, 69:394-397.
33. Damiano M., Gautier C.A., Bulteau A.L., Ferrando-Miguel R., Gouarne C., Paoli M.G., et al. Tissue- and cell-specific mitochondrial defect in parkin-deficient mice. PLoS ONE 2014, 9:e99898.
34. Deleersnijder A., Gerard M., Debyser Z., Baekelandt V. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?. Trends in Molecular Medicine 2013, 19:368-377.
35. Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., Cookson M.R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1499-1504.
36. Dev K.K., van der Putten H., Sommer B., Rovelli G. Part I: parkin-associated proteins and Parkinson's disease. Neuropharmacology 2003, 45:1-13.
37. Devi L., Anandatheerthavarada H.K. Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochimica et Biophysica Acta 2010, 1802:11-19.
38. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. The Journal of Biological Chemistry 2008, 283:9089-9100.
39. DeWitt M.R., Chen P., Aschner M. Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations. Biochemical and Biophysical Research Communications 2013, 432:1-4.
40. Eiberg H., Hansen L., Korbo L., Nielsen I.M., Svenstrup K., Bech S., et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clinical Genetics 2012, 82:256-263.
41. Erikson K.M., John C.E., Jones S.R., Aschner M. Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. Environmental Toxicology and Pharmacology 2005, 20:390-394.
42. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:12413-12418.
43. Finkelstein Y., Milatovic D., Aschner M. Modulation of cholinergic systems by manganese. Neurotoxicology 2007, 28:1003-1014.
44. Follett J., Norwood S.J., Hamilton N.A., Mohan M., Kovtun O., Tay S., et al. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic 2014, 15:230-244.
45. Fordahl S.C., Erikson K.M. Manganese accumulation in membrane fractions of primary astrocytes is associated with decreased gamma-aminobutyric acid (GABA) uptake, and is exacerbated by oleic acid and palmitate. Environmental Toxicology and Pharmacology 2014, 37:1148-1156.
46. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain: A Journal of Neurology 2006, 129:1720-1731.
47. Garrick M.D., Singleton S.T., Vargas F., Kuo H.C., Zhao L., Knopfel M., et al. DMTI: Which metals does it transport?. Biological Research 2006, 39:79-85.
48. Garrick M.D., Zhao L., Roth J.A., Jiang H., Feng J., Foot N.J., et al. Isoform specific regulation of divalent metal (ion) transporter (DMT1) by proteasomal degradation. Biometals: An International Journal on the role of Metal Ions in Biology, Biochemistry, and Medicine 2012, 25:787-793.
49. Gavin C.E., Gunter K.K., Gunter T.E. Manganese and calcium transport in mitochondria: implications for manganese toxicity. Neurotoxicology 1999, 20:445-453.
50. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biology 2010, 12:119-131.
51. Giaime E., Yamaguchi H., Gautier C.A., Kitada T., Shen J. Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening. PLoS ONE 2012, 7:e40501.
52. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature Genetics 2009, 41:308-315.
53. Gloeckner C.J., Schumacher A., Boldt K., Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. Journal of Neurochemistry 2009, 109:959-968.
54. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999, 20:239-247.
55. Greggio E., Bisaglia M., Civiero L., Bubacco L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?. Molecular Neurodegeneration 2011, 6:6.
56. Guilarte T.R., Burton N.C., McGlothan J.L., Verina T., Zhou Y., Alexander M., et al. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. Journal of Neurochemistry 2008, 107:1236-1247.
57. Guilarte T.R., Chen M.K., McGlothan J.L., Verina T., Wong D.F., Zhou Y., et al. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Experimental Neurology 2006, 202:381-390.
58. Gunter T.E., Gavin C.E., Gunter K.K. The case for manganese interaction with mitochondria. Neurotoxicology 2009, 30:727-729.
59. Gusdon A.M., Zhu J., Van Houten B., Chu C.T. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiology of Disease 2012, 45:962-972.
60. Habig K., Walter M., Poths S., Riess O., Bonin M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 2008, 9:83-94.
61. Haque M.E., Mount M.P., Safarpour F., Abdel-Messih E., Callaghan S., Mazerolle C., et al. Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. The Journal of Biological Chemistry 2012, 287:23162-23170.
62. Hauser R.A., Zesiewicz T.A. Manganese and chronic liver disease. Movement Disorders: Official Journal of the Movement Disorder Society 1996, 11:589.
63. Hedrich K., Djarmati A., Schafer N., Hering R., Wellenbrock C., Weiss P.H., et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004, 62:389-394.
64. Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y., Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. Journal of Neurochemistry 2004, 89:1490-1497.
65. Hirata Y., Adachi K., Kiuchi K. Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells. Journal of Neurochemistry 1998, 71:1607-1615.
66. Hongge L., Kexin G., Xiaojie M., Nian X., Jinsha H. The role of LRRK2 in the regulation of monocyte adhesion to endothelial cells. Journal of Molecular Neuroscience: MN 2014, in press.
67. Houlden H., Singleton A.B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathologica 2012, 124:325-338.
68. Hsu C.H., Chan D., Wolozin B. LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neuro-Degenerative Diseases 2010, 7:68-75.
69. Hubert N., Hentze M.W. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:12345-12350.
70. Hudnell H.K. Effects from environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Neurotoxicology 1999, 20:379-397.
71. Hyun D.H., Lee M., Halliwell B., Jenner P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. Journal of Neuroscience Research 2005, 82:232-244.
72. Ingrassia R., Lanzillotta A., Sarnico I., Benarese M., Blasi F., Borgese L., et al. 1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-kappaB/RelA acetylation at Lys310. PLoS ONE 2012, 7:e38019.
73. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. The Biochemical Journal 2007, 405:307-317.
74. Joselin A.P., Hewitt S.J., Callaghan S.M., Kim R.H., Chung Y.H., Mak T.W., et al. ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons. Human Molecular Genetics 2012, 21:4888-4903.
75. Junn E., Jang W.H., Zhao X., Jeong B.S., Mouradian M.M. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. Journal of Neuroscience Research 2009, 87:123-129.
76. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neuroscience Letters 2002, 320:146-150.
77. Kane L.A., Lazarou M., Fogel A.I., Li Y., Yamano K., Sarraf S.A., et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. The Journal of Cell Biology 2014, 205:143-153.
78. Karki P., Lee E., Aschner M. Manganese neurotoxicity: a focus on glutamate transporters. Annals of Occupational and Environmental Medicine 2013, 25:4.
79. Kazlauskaite A., Kondapalli C., Gourlay R., Campbell D.G., Ritorto M.S., Hofmann K., et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. The Biochemical Journal 2014, 460:127-139.
80. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., et al. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS ONE 2012, 7:e34693.
81. Kim Y., Kim J.M., Kim J.W., Yoo C.I., Lee C.R., Lee J.H., et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?. Movement Disorders: Official Journal of the Movement Disorder Society 2002, 17:568-575.
82. Kondo K., Obitsu S., Teshima R. alpha-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biological & Pharmaceutical Bulletin 2011, 34:1078-1083.
83. Kong S.M., Chan B.K., Park J.S., Hill K.J., Aitken J.B., Cottle L., et al. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes alpha-Synuclein externalization via exosomes. Human Molecular Genetics 2014, 23:2816-2833.
84. Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M., et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 2014, 510:162-166.
85. Lam-Yuk-Tseung S., Touret N., Grinstein S., Gros P. Carboxyl-terminus determinants of the iron transporter DMT1/SLC11A2 isoform II (-IRE/1B) mediate internalization from the plasma membrane into recycling endosomes. Biochemistry 2005, 44:12149-12159.
86. Lazarou M., Narendra D.P., Jin S.M., Tekle E., Banerjee S., Youle R.J. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. The Journal of Cell Biology 2013, 200:163-172.
87. Lechpammer M., Clegg M.S., Muzar Z., Huebner P.A., Jin L.W., Gospe S.M. Pathology of inherited manganese transporter deficiency. Annals of Neurology 2014, 75:608-612.
88. Lee E., Yin Z., Sidoryk-Wegrzynowicz M., Jiang H., Aschner M. 15-Deoxy-Delta12, 14-prostaglandin J(2) modulates manganese-induced activation of the NF-kappaB, Nrf2, and PI3K pathways in astrocytes. Free Radical Biology & Medicine 2012, 52:1067-1074.
89. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics 2009, 18:R48-R59.
90. Lev N., Ickowicz D., Barhum Y., Lev S., Melamed E., Offen D. DJ-1 protects against dopamine toxicity. Journal of Neural Transmission 2009, 116:151-160.
91. Lill C.M., Roehr J.T., McQueen M.B., Kavvoura F.K., Bagade S., Schjeide B.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genetics 2012, 8:e1002548.
92. Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y., et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2005, 25:2002-2009.
93. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
94. Liu W., Vives-Bauza C., Acin-Perez R., Yamamoto A., Tan Y., Li Y., et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS ONE 2009, 4:e4597.
95. Lovitt B., Vanderporten E.C., Sheng Z., Zhu H., Drummond J., Liu Y. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). Biochemistry 2010, 49:3092-3100.
96. MacLeod D.A., Rhinn H., Kuwahara T., Zolin A., Di Paolo G., McCabe B.D., et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013, 77:425-439.
97. Mamais A., Raja M., Manzoni C., Dihanich S., Lees A., Moore D., et al. Divergent alpha-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiology of Disease 2013, 58:183-190.
98. Manning-Bog A.B., Caudle W.M., Perez X.A., Reaney S.H., Paletzki R., Isla M.Z., et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiology of Disease 2007, 27:141-150.
99. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1988, 8:2804-2815.
100. Marques O., Outeiro T.F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death & Disease 2012, 3:e350.
101. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neurosciences 2006, 29:286-293.
102. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. The Journal of Cell Biology 2010, 189:211-221.
103. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
104. Milatovic D., Yin Z., Gupta R.C., Sidoryk M., Albrecht J., Aschner J.L., et al. Manganese induces oxidative impairment in cultured rat astrocytes. Toxicological Sciences: An Official Journal of the Society of Toxicology 2007, 98:198-205.
105. Moore D.J., Zhang L., Troncoso J., Lee M.K., Hattori N., Mizuno Y., et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics 2005, 14:71-84.
106. Muqit M.M., Abou-Sleiman P.M., Saurin A.T., Harvey K., Gandhi S., Deas E., et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. Journal of Neurochemistry 2006, 98:156-169.
107. Nakamura K. alpha-Synuclein and mitochondria: partners in crime?. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2013, 10:391-399.
108. Nakamura K., Nemani V.M., Azarbal F., Skibinski G., Levy J.M., Egami K., et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. The Journal of Biological Chemistry 2011, 286:20710-20726.
109. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71:1790-1795.
110. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. The Journal of Cell Biology 2008, 183:795-803.
111. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biology 2010, 8:e1000298.
112. Nie K., Zhang Y., Huang B., Wang L., Zhao J., Huang Z., et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism & Related Disorders 2013, 19:329-334.
113. Ning Y.P., Kanai K., Tomiyama H., Li Y., Funayama M., Yoshino H., et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008, 70:1491-1493.
114. Olanow C.W., Good P.F., Shinotoh H., Hewitt K.A., Vingerhoets F., Snow B.J., et al. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996, 46:492-498.
115. Pal P.K., Samii A., Calne D.B. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology 1999, 20:227-238.
116. Pallanck L., Greenamyre J.T. Neurodegenerative disease: pink, parkin and the brain. Nature 2006, 441:1058.
117. Paradkar P.N., Roth J.A. Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by retinoic acid. The Biochemical Journal 2006, 394:173-183.
118. Paradkar P.N., Roth J.A. Expression of the 1B isoforms of divalent metal transporter (DMT1) is regulated by interaction of NF-Y with a CCAAT-box element near the transcription start site. Journal of Cellular Physiology 2007, 211:183-188.
119. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
120. Park J.S., Mehta P., Cooper A.A., Veivers D., Heimbach A., Stiller B., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Human Mutation 2011, 32:956-964.
121. Park N.H., Park J.K., Choi Y., Yoo C.I., Lee C.R., Lee H., et al. Whole blood manganese correlates with high signal intensities on T1-weighted MRI in patients with liver cirrhosis. Neurotoxicology 2003, 24:909-915.
122. Peneder T.M., Scholze P., Berger M.L., Reither H., Heinze G., Bertl J., et al. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice. Neuroscience 2011, 180:280-292.
123. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:3338-3346.
124. Pham C.L., Leong S.L., Ali F.E., Kenche V.B., Hill A.F., Gras S.L., et al. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. Journal of Molecular Biology 2009, 387:771-785.
125. Pifl C., Khorchide M., Kattinger A., Reither H., Hardy J., Hornykiewicz O. alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter. Neuroscience Letters 2004, 354:34-37.
126. Plowey E.D., Johnson J.W., Steer E., Zhu W., Eisenberg D.A., Valentino N.M., et al. Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration. Biochimica et Biophysica Acta 2014, 1842:1596-1603.
127. Podhajska A., Musso A., Trancikova A., Stafa K., Moser R., Sonnay S., et al. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. PLoS ONE 2012, 7:e39942.
128. Prabhakaran K., Chapman G.D., Gunasekar P.G. alpha-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-kappaB-mediated pathway. Toxicology Mechanisms and Methods 2011, 21:435-443.
129. Puschmann A., Verbeeck C., Heckman M.G., Soto-Ortolaza A.I., Lynch T., Jasinska-Myga B., et al. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism & Related Disorders 2011, 17:376-378.
130. Quadri M., Federico A., Zhao T., Breedveld G.J., Battisti C., Delnooz C., et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. American Journal of Human Genetics 2012, 90:467-477.
131. 18F]FDOPA PET and clinical features in parkinsonism due to manganism. Movement Disorders: Official Journal of the Movement Disorder Society 2005, 20:492-496.
132. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001, 56:8-13.
133. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics 2006, 38:1184-1191.
134. Ramonet D., Podhajska A., Stafa K., Sonnay S., Trancikova A., Tsika E., et al. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Human Molecular Genetics 2012, 21:1725-1743.
135. Rentschler G., Covolo L., Haddad A.A., Lucchini R.G., Zoni S., Broberg K. ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. Neurotoxicology 2012, 33:697-702.
136. Rhodes S.L., Sinsheimer J.S., Bordelon Y., Bronstein J.M., Ritz B. Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Annals of Human Genetics 2011, 75:195-200.
137. Robison G., Zakharova T., Fu S., Jiang W., Fulper R., Barrea R., et al. X-ray fluorescence imaging: a new tool for studying manganese neurotoxicity. PLoS ONE 2012, 7:e48899.
138. Ross O.A., Soto-Ortolaza A.I., Heckman M.G., Aasly J.O., Abahuni N., Annesi G., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurology 2011, 10:898-908.
139. Roth J.A. Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. Biological Research 2006, 39:45-57.
140. Roth J.A. Are there common biochemical and molecular mechanisms controlling manganism and parkisonism. Neuromolecular Medicine 2009, 11:281-296.
141. Roth J.A., Eichhorn M. Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity. Neurotoxicology 2013, 37:100-107.
142. Roth J.A., Feng L., Walowitz J., Browne R.W. Manganese-induced rat pheochromocytoma (PC12) cell death is independent of caspase activation. Journal of Neuroscience Research 2000, 61:162-171.
143. Roth J.A., Ganapathy B., Ghio A.J. Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin. Toxicology in Vitro: An International Journal Published in Association with BIBRA 2012, 26:1143-1149.
144. Roth J.A., Li Z., Sridhar S., Khoshbouei H. The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells. Neurotoxicology 2013, 35:121-128.
145. Roth J.A., Singleton S., Feng J., Garrick M., Paradkar P.N. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. Journal of Neurochemistry 2010, 113:454-464.
146. Russo I., Bubacco L., Greggio E. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. Journal of Neuroinflammation 2014, 11:52.
147. Sadek A.H., Rauch R., Schulz P.E. Parkinsonism due to manganism in a welder. International Journal of Toxicology 2003, 22:393-401.
148. Saha S., Guillily M.D., Ferree A., Lanceta J., Chan D., Ghosh J., et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2009, 29:9210-9218.
149. Santoro L., Breedveld G.J., Manganelli F., Iodice R., Pisciotta C., Nolano M., et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2010, 22:33-39.
150. Santpere G., Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathologica 2009, 117:227-246.
151. 2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochemical and Biophysical Research Communications 2009, 383:198-202.
152. Schultheis P.J., Hagen T.T., O'Toole K.K., Tachibana A., Burke C.R., McGill D.L., et al. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochemical and Biophysical Research Communications 2004, 323:731-738.
153. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathologica 2010, 120:131-143.
154. Sha D., Chin L.S., Li L. Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Human Molecular Genetics 2010, 19:352-363.
155. Sharma M., Ioannidis J.P., Aasly J.O., Annesi G., Brice A., Bertram L., et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics 2012, 49:721-726.
156. Shaw G.S. Switching on ubiquitylation by phosphorylating a ubiquitous activator. The Biochemical Journal 2014, 460:e1-e3.
157. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Annals of Neurology 1999, 45:668-672.
158. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., et al. LRRK2 regulates synaptic vesicle endocytosis. Experimental Cell Research 2008, 314:2055-2065.
159. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
160. Sriram K., Lin G.X., Jefferson A.M., Roberts J.R., Wirth O., Hayashi Y., et al. Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2010, 24:4989-5002.
161. Stamelou M., Tuschl K., Chong W.K., Burroughs A.K., Mills P.B., Bhatia K.P., et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Movement Disorders: Official Journal of the Movement Disorder Society 2012, 27:1317-1322.
162. Swan M., Saunders-Pullman R. The association between ss-glucocerebrosidase mutations and parkinsonism. Current Neurology and Neuroscience Reports 2013, 13:368.
163. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics 2000, 9:2683-2689.
164. Tabuchi M., Yoshimori T., Yamaguchi K., Yoshida T., Kishi F. Human NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is localized to late endosomes and lysosomes in HEp-2 cells. The Journal of Biological Chemistry 2000, 275:22220-22228.
165. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Reports 2004, 5:213-218.
166. Tan J., Zhang T., Jiang L., Chi J., Hu D., Pan Q., et al. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. The Journal of Biological Chemistry 2011, 286:29654-29662.
167. Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der Brug M., Sandebring A., et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Human Molecular Genetics 2011, 20:40-50.
168. Thomas R.E., Andrews L.A., Burman J.L., Lin W.Y., Pallanck L.J. PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. PLoS Genetics 2014, 10:e1004279.
169. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14622-14627.
170. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:9879-9884.
171. Tsunemi T., Krainc D. Zn(2)(+) dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Human Molecular Genetics 2014, 23:2791-2801.
172. Tuschl K., Clayton P.T., Gospe S.M., Gulab S., Ibrahim S., Singhi P., et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. American Journal of Human Genetics 2012, 90:457-466.
173. ® [Internet] 2012, University of Washington, Seattle, Seattle (WA), 1993-2014. R.A. Pagon (Ed.).
174. Ugolino J., Fang S., Kubisch C., Monteiro M.J. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Human Molecular Genetics 2011, 20:3565-3577.
175. Usenovic M., Knight A.L., Ray A., Wong V., Brown K.R., Caldwell G.A., et al. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Human Molecular Genetics 2012, 21:3785-3794.
176. Usenovic M., Krainc D. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9. Autophagy 2012, 8:987-988.
177. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
178. van Veen S., Sorensen D.M., Holemans T., Holen H.W., Palmgren M.G., Vangheluwe P. Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders. Frontiers in Molecular Neuroscience 2014, 7:48.
179. Verina T., Kiihl S.F., Schneider J.S., Guilarte T.R. Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology 2011, 32:215-226.
180. Verina T., Schneider J.S., Guilarte T.R. Manganese exposure induces alpha-synuclein aggregation in the frontal cortex of non-human primates. Toxicology Letters 2013, 217:177-183.
181. Vilarino-Guell C., Wider C., Ross O.A., Dachsel J.C., Kachergus J.M., Lincoln S.J., et al. VPS35 mutations in Parkinson disease. American Journal of Human Genetics 2011, 89:162-167.
182. Vives-Bauza C., Przedborski S. PINK1 points Parkin to mitochondria. Autophagy 2010, 6:674-675.
183. Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J., et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:378-383.
184. Wang Y., Nartiss Y., Steipe B., McQuibban G.A., Kim P.K. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mitochondrial degradation by autophagy. Autophagy 2012, 8:1462-1476.
185. Watson J.B., Hatami A., David H., Masliah E., Roberts K., Evans C.E., et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009, 159:501-513.
186. Wider C., Wszolek Z.K. Clinical genetics of Parkinson's disease and related disorders. Parkinsonism & Related Disorders 2007, 13(Suppl. 3):S229-S232.
187. Wilhelmus M.M., Nijland P.G., Drukarch B., de Vries H.E., van Horssen J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radical Biology & Medicine 2012, 53:983-992.
188. Wu X., Tang K.F., Li Y., Xiong Y.Y., Shen L., Wei Z.Y., et al. Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. Parkinsonism & Related Disorders 2012, 18:722-730.
189. Xiong H., Wang D., Chen L., Choo Y.S., Ma H., Tang C., et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. The Journal of Clinical Investigation 2009, 119:650-660.
190. Xu B., Wu S.W., Lu C.W., Deng Y., Liu W., Wei Y.G., et al. Oxidative stress involvement in manganese-induced alpha-synuclein oligomerization in organotypic brain slice cultures. Toxicology 2013, 305:71-78.
191. Yang Y., An J., Wang Y., Luo W., Wang W., Mei X., et al. Intrastriatal manganese chloride exposure causes acute locomotor impairment as well as partial activation of substantia nigra GABAergic neurons. Environmental Toxicology and Pharmacology 2011, 31:171-178.
192. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10793-10798.
193. Yang Y.X., Wood N.W., Latchman D.S. Molecular basis of Parkinson's disease. Neuroreport 2009, 20:150-156.
194. Zhang J., Cao R., Cai T., Aschner M., Zhao F., Yao T., et al. The role of autophagy dysregulation in manganese-induced dopaminergic neurodegeneration. Neurotoxicity Research 2013, 24:478-490.
195. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics 2005, 14:2063-2073.
196. Zimprich A., Benet-Pages A., Struhal W., Graf E., Eck S.H., Offman M.N., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. American Journal of Human Genetics 2011, 89:168-175.
197. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.